ITM Isotope Technologies Munich SE and Lumara Bio presented data at EANM 2026 showing that higher absorbed doses of ¹⁷⁷Lu-edotreotide in tumors correlate with improved clinical response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 COMPETE trial analysis revealed that patients receiving higher cumulative doses had significantly better objective response rates, suggesting potential for more personalized radiopharmaceutical treatments. Additionally, early-stage data for other pipeline candidates like Ga-DPI-4452 for renal cancer and Tb-DOTA-LM3 for SSTR-positive tumors were shared, supporting ongoing development of targeted therapies for difficult cancers.
The ITM and Lumara Bio dose-response analysis and early-stage pipeline data provide context for healthcare sector activity. For readers following healthcare stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:43 WIB: out of 150 priced US health-sector stocks, 89 rose and 58 fell. Notable movers include NVAX at USD 10.62 with a 1-day change of -1.89%, ALC at USD 67.33 with a 1-day change of +1.81%, and NUVB at USD 4.40 with a 1-day change of -1.79%.
Synchrony Financial reported Q3 2026 earnings per share of $2.68 and revenue of $4.91 billion, both exceeding analyst expectations. However, net profit fell to $892 million from $1.1 billion the previous year due to higher operating costs, even as cr...
Hancock Whitney is set to report its Q3 2026 earnings on October 20, with analysts forecasting earnings per share between $1.65 and $1.66 and revenue estimates from $418.85 million to $422 million. Despite year-over-year growth projections, indicator...
In September 2026, New York State's housing inventory increased by 9.8% year-over-year, reaching 35,294 homes available for sale. Despite this rise in supply, home prices continued to grow, with the median sales price up 5.9% to $450,000 compared to ...
The Europe Electronic Health Record (EHR) market is projected to grow from $8.05 billion in 2024 to $15.37 billion by 2031, at a compound annual growth rate of 9.9%. Growth is fueled by increasing EHR adoption, government digital health programs, and...
EssilorLuxottica reported a 9.0% increase in revenue for Q3 2026, reaching €7,486 million, with a 7.2% rise at constant exchange rates. Growth was broad-based, with strong double-digit increases in Asia-Pacific and the Direct to Consumer segment up 1...
